Expanding TIL Clinical Activity Beyond Melanoma by Selectively Enriching Tumor Reactive T-cells

• Demonstrating clinical feasibility of isolating tumor reactive T-cells across multiple solid tumor types
• Sharing early phase safety and response observations from a selective TIL approach
• Informing future trial design by linking cell composition to clinical outcomes

Speakers:

Andrew Weinberg

President & Chief Scientific Officer

AgonOx